LXRX (Lexicon Pharmaceuticals) Change In Receivables: $0.54 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LXRX Lexicon Pharmaceuticals Inc LXRX
42 GF Score
Price $2.33
! 7 Warning Signs
View Full Analysis

What is Lexicon Pharmaceuticals Change In Receivables?

Lexicon Pharmaceuticals LXRX +0.43% 42 Change In Receivables is $0.54 Mil as of Jun. 2026. GuruFocus rates LXRX with a GF Score™ of 42/100. The stock has 7 warning signs investors should review.

Lexicon Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2026 was $10.14 Mil. It means Lexicon Pharmaceuticals's Accounts Receivable declined by $10.14 Mil from Mar. 2026 to Jun. 2026 .

Lexicon Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was $1.09 Mil. It means Lexicon Pharmaceuticals's Accounts Receivable declined by $1.09 Mil from Dec. 2024 to Dec. 2025 .

Lexicon Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2026 was $1.64 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lexicon Pharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2026 was 216.65.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lexicon Pharmaceuticals's liquidation value for the three months ended in Jun. 2026 was $116.91 Mil.

Lexicon Pharmaceuticals  (NAS:LXRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lexicon Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.643/0.692*91
=216.65

2. In Ben Graham's calculation of liquidation value, Lexicon Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Lexicon Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=190.61-75.535+0.75 * 1.643+0.5 * 1.196
=116.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals Change In Receivables Related Terms

Lexicon Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Lexicon Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals Change In Receivables Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 -0.01 -0.98 -2.46 1.09

Lexicon Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 -0.15 -0.05 -9.40 10.14
LXRX
42GF Score
Lexicon Pharmaceuticals Inc LXRX
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexicon Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.54 Mil mean?
Lexicon Pharmaceuticals (LXRX) has a Change In Receivables of $0.54 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Lexicon Pharmaceuticals and its competitors.
Is Lexicon Pharmaceuticals' Change In Receivables too high?
Lexicon Pharmaceuticals' current Change In Receivables is $0.54 Mil. Overall, Lexicon Pharmaceuticals has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Lexicon Pharmaceuticals' Change In Receivables compare to EYPT and OLMA?
Lexicon Pharmaceuticals' Change In Receivables of $0.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Lexicon Pharmaceuticals and its competitors. Lexicon Pharmaceuticals's current Change In Receivables is $0.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexicon Pharmaceuticals stock overvalued right now?
Lexicon Pharmaceuticals (LXRX) has a current Change In Receivables of $0.54 Mil. The current Change In Receivables is $0.54 Mil. Lexicon Pharmaceuticals' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Lexicon Pharmaceuticals (LXRX), the current Change In Receivables is $0.54 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexicon Pharmaceuticals Business Description

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
42GF Score

Get the complete analysis for LXRX

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price